BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

September 17, 2012 7:00 AM UTC

Cornerstone Therapeutics Inc. (NASDAQ:CRTX) fell $1.37 (21%) to $5.10 on Thursday after FDA's Cardiovascular and Renal Drugs Advisory Committee recommended against approval of lixivaptan to treat hypervolemic hyponatremia associated with chronic heart failure (CHF) and euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH). The committee voted 8-0 against the CHF indication and 5-3 against the SIADH indication. The product has an Oct. 29 PDUFA date.

The stock lost $1.08 (18%) to $5.06 on the week...